Monograph

J01MA06 - Norfloxacin

Propably not porphyrinogenic

Rationale

CYP 3A4-inhibitor. Conflicting references but some clinical experience of non-porphyrinogenicity.

Chemical description

Quinolone antibiotic. Some metabolism takes place and several metabolites have been identified in urine. About 30% is excreted in urine in unchanged form within 24 hours, while the same amount is recoverd in faeces. Inhibitor of CYP 3A4. Some interference with fluorimetric determination of urinary porphyrins, reported. Australian list: safe. South African list: use with extreme caution only. French list: use. S Thunell, patient inquiry: well tolerated(n=4). Andersson:

IPNet drug reports

Uneventful use reported in 18 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes J01M / J01MA or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands